Publikace se zaměřuje na současné techniky laboratorní hematologické diagnostiky. Určeno odborné veřejnosti.

• MeSH
• hematologické testy MeSH
• klinické laboratorní techniky MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• hematologie a transfuzní lékařství
• NLK Publikační typ
• kolektivní monografie

Polymorfismus genotypu a fenotypu a jeho yužití pro diferenciální diagnostiku, terapii a prognostiku. XXX XXX XXX

• MeSH
• diferenciální diagnóza MeSH
• fenotyp MeSH
• genotyp MeSH
• polymorfismus genetický MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• embryologie a teratologie
• radiologie, nukleární medicína a zobrazovací metody
• pediatrie
• genetika, lékařská genetika
• chemie, klinická chemie
• NLK Publikační typ
• závěrečné zprávy o řešení grantu IGA MZ ČR

• Publikační typ
• abstrakty MeSH

• Publikační typ
• abstrakt z konference MeSH

Antonín Přecechtěl se narodil 6. listopadu 1885 v obci Srbce na Prostějovsku v rodině rolníka z Hané. Maturoval na gymnáziu v Kroměříži, lékařství studoval na České Lékařské fakultě Karlo-Ferdinandovy univerzity v Praze. Po promoci v roku 1910 nastoupil na chirurgickou kliniku prof. Kukuly v Praze. Jako chirurg se zúčastnil balkánských válek i první světové války. V roce 1918 nastoupil na Ušní kliniku prof. Kutvirta v Praze, kde se v roce 1920 habilitoval z otologie-faryngologie a již v roce 1924 byl jmenován mimořádným profesorem. Po smrti prof. Kutvirta se v roce 1930 stal přednostou kliniky, téhož roku se habilitoval i z rino-laryngologie, a dovršil tak proces sjednocení výuky otorinolaryngologie jako jednoho oboru. Funkci přednosty otolaryngologické kliniky vykonával 30 let. Byl zakládajícím členem České otolaryngologické společnosti (1921) a v letech 1935–1951 byl jejím předsedou. V roce 1926 se jako zakládající člen účastnil vzniku prestižní organizace Collegium Oto-Rhino-Laryngologicum Amicitiae Sacrum. Podílel se i na založení a vedení mezinárodního časopisu Otolaryngologia Slavica, od roku 1952 začal z jeho iniciativy vycházet časopis Československá otolaryngologie. Výsledky vědecké práce zveřejnil prof. Přecechtěl v téměř 400 publikacích v domácí i zahraniční odborné literatuře. Angažoval se i v laboratorním a experimentálním bádání, zejména o vestibulárním aparátu. V roce 1954 byl jmenován řádným členem Československé akademie věd, ve které založil Otolaryngologickou laboratoř. Prof. Přecechtěl vytvořil vlastní otorinolaryngologickou školu a vyškolil řadu odborníků. Zemřel 5. února 1971 ve věku 85 let.

Antonín Přecechtěl was born on 6 November 1885 in the village of Srbce in the Prostějov region (Moravia) in a peasant's family. He graduated from the secondary grammar school in Kroměříž and studied medicine at the Czech Medical Faculty of the Charles-Ferdinand University in Prague. After graduating in 1910, he started his career as a surgeon at prof. Kukula's surgery clinic in Prague. As a surgeon, he participated in the Balkan Wars and the First World War. In 1918 he began to work at prof. Kutvirt's ear clinic in Prague. Here he obtained habilitation in otology and pharyngology in 1920, and in 1924 he was appointed associate professor. After Kutvirt's death, he became the head of the clinic in 1930, and in the same year, he also received habilitation in rhino-laryngology, thus completing the process of unifying the teaching of otorhinolaryngology as one field. He held the position of head of the Otolaryngology Clinic for 30 years. He was a founding member of the Czech Otolaryngological Society (1921) and in the period 1935–1951, he was its chairman. In 1926, as a founding member, he participated in the founding of the prestigious organization Collegium Oto-Rhino-Laryngologicum Amicitiae Sacrum. He also participated in the establishment and management of the international journal Otolaryngologia Slavica, and the journal Czechoslovak Otolaryngology began to be published in 1952 on his initiative. The results of his scientific work have been published in almost 400 publications in both domestic and foreign journals. Přecechtěl was also involved in laboratory and experimental research, especially on the vestibular apparatus. In 1954 he was appointed a full member of the Czechoslovak Academy of Sciences, in which he founded the Otolaryngological Laboratory. Professor Přecechtěl created his own otorhinolaryngology school and trained many experts. He died on 5 February 1971, at the age of 85.

• MeSH
• otorinolaryngologie * MeSH
• Publikační typ
• biografie MeSH

• O autorovi
• Přecechtěl, Antonín, 1885-1971 Autorita

BACKGROUND: β2-Glycoprotein I (β2GPI) represents the major antigenic target for antiphospholipid antibodies (aPL), with domain 1 (D1) being identified as a risk factor for thrombosis and pregnancy complications in APS. We aimed to analyse the ability of aPL, and particularly anti-D1 β2GPI, to stimulate prothrombotic and proinflammatory activity of immune cells in vitro. METHODS: Peripheral blood mononuclear cells (PBMCs) from 11 healthy individuals were incubated with: (1) "anti-D1(+)"-pooled plasma derived from patients suspected of having APS contained anticardiolipin antibodies (aCL), lupus anticoagulant (LA), anti-β2GPI and anti-D1 β2GPI; (2) "anti-D1(-)"-pooled plasma from patients suspected of having APS contained aCL, LA, anti-β2GPI, and negative for anti-D1 β2GPI; (3) "seronegative"-negative for aPL. RESULTS: The presence of anti-D1(+) and anti-D1(-) plasma resulted in increased HLA-DR and CD11b on monocytes. While only anti-D1(+) plasma markedly increased the percentage and median fluorescence intensity (MFI) of CD142 (tissue factor, TF) on monocytes in comparison with those cultured with anti-D1(-) and seronegative plasma. Anti-D1(+) plasma resulted in increased percentage and MFI of activation marker CD69 on NK and T cytotoxic cells. Expression of IgG receptor FcγRIII(CD16) on monocytes and NK cells was down-regulated by the anti-D1(+) plasma. CONCLUSIONS: Taking together, our study shows the ability of patient-derived aPL to induce immune cell activation and TF expression on monocytes. For the first time, we demonstrated the influence of anti-D1 β2GPI on the activation status of monocytes, NK and cytotoxic T cells. Our findings further support a crucial role of D1 epitope in the promotion of thrombosis and obstetrical complications in APS.

• Publikační typ
• časopisecké články MeSH

Antiphospholipid syndrome (APS) is a hypercoagulation condition associated with the incidence of heterogenic antiphospholipid antibodies (aPLs), which non-specifically affect hemostasis processes. APS is clinically manifested by recurrent arterial and venous thromboses and reproduction losses. The aPL antibodies, which may induce clinical manifestations of APS, include criteria antibodies anti-cardiolipin, anti-β2-glycoprotein-I, and lupus anticoagulant, but also non-criteria antibodies, for example anti-β2-glycoprotein-I domain I, anti-phosphatidylserine/prothrombin, anti-annexin V, and many others. APS occurs mostly in patients of younger and middle age, most frequently in females. Laboratory diagnostics of APS are quite difficult, as they include a wide spectrum of examining methods, which are based on various principles of detection and are performed using various laboratory techniques. The objective of the review is to describe the current state of potentially examined biomarkers and methods in APS diagnostics. The aforementioned biomarkers are lupus anticoagulant, anti-β2-glycoprotein-I, anti-cardiolipin, anti-β2-glycoprotein-I domain I, anti-phosphatidylserine/prothrombin, anti-β2-glycoprotein-I IgA, anti-cardiolipin IgA, anti-annexin V and II, anti-prothrombin, anti-cardiolipin/vimentin, anti-protein S/protein C, and antibodies against phospholipid antigens for whose diagnostics we may use some of the methods established for a long time and some of the modern methods-the coagulation method for the determination of lupus anticoagulant (LA), enzyme-linked imunosorbent assay (ELISA), chemiluminescence analysis (CLIA), multiplex fluorescence flow immunoassay (MFFIA), fluorescence enzyme immunoassay (EliA), line immunoassay (LIA), multiline dot assay (MLDA), and thin-layer chromatography (TLC). Conclusion: Antibodies against phosphatidylethanolamine, phosphatidic acid, phosphatidylserine, phosphatidylinositol, cardiolipin/vimentin complex, and annexin V are currently the most studied new markers. However, these assays have not been standardized until now, both from the laboratory and clinical point of view. In this review we summarize the evidence of the most studied aPL markers and their potential clinical significance in seronegative APS (SN-APS).

• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

Antiphospholipid syndrome (APS) is a hypercoagulable state accompanied by the presence of heterogeneous antiphospholipid antibodies (aPL), which nonspecifically affect hemostasis by the presence of lupus anticoagulans (LA), anticardiolipin antibodies (aCL), antibodies against β2-glycoprotein-I (anti-β2GPI), but also non-criteria antibodies such as antibodies against β2-glycoprotein-I domain I (anti-DI), anti-phosphatidylserine/prothrombin (anti-PS/PT), anti-annexin V, and many others. The main target of the antibodies is the activated protein C (APC) system, the elimination of which can manifest itself as a thrombotic complication. The aim of this study was to determine the thrombogenicity of antibodies using a modified protein C-activated thrombin generation assay (TGA) on a group of 175 samples suspected of APS. TGA was measured with/without APC and the ratio of both measurements was evaluated (as for APC resistance), where a cut-off was calculated ≤4.5 (90th percentile) using 21 patients with heterozygous factor V Leiden mutation (FV Leiden heterozygous). Our study demonstrates the well-known fact that multiple positivity of different aPLs is a more severe risk for thrombosis than single positivity. Of the single antibody positivity, LA antibodies are the most serious (p value < 0.01), followed by aCL and their subgroup anti-DI (p value < 0.05). Non-criteria antibodies anti-annexin V and anti-PT/PS has a similar frequency occurrence of thrombogenicity as LA antibodies but without statistical significance or anti-β2GPI1 positivity. The modified TGA test can help us identify patients in all groups who are also at risk for recurrent thrombotic and pregnancy complications; thus, long-term prophylactic treatment is appropriate. For this reason, it is proving increasingly beneficial to include the determination antibodies in combination with modified TGA test.

• MeSH
• antifosfolipidové protilátky MeSH
• antifosfolipidový syndrom * komplikace   MeSH
• antikardiolipinové protilátky MeSH
• beta-2-glykoprotein I MeSH
• fosfatidylseriny MeSH
• lidé MeSH
• protein C MeSH
• protrombin MeSH
• těhotenství MeSH
• trombin MeSH
• trombóza * etiologie   MeSH
• Check Tag
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

The aim of this study was to determine the thrombogenicity of lupus anticoagulant (LA) antibodies using a modified thrombin generation assay (TGA) with the addition of activated protein C (APC) in a group of 85 patients with LA-positive samples. Of these, 58 patients had clinical manifestations of antiphospholipid syndrome (APS) according to the Sydney criteria classification, i.e., each patient had thrombosis or foetal loss, and 27 patients did not show any clinical manifestations of APS. A comparison of the two groups' TGA results revealed statistically significant differences (Fisher's test p = 0.0016). The group of patients exhibiting clinical manifestations of APS showed higher thrombogenicity in 56.9% of patients, while the group of patients not yet exhibiting clinical manifestations of APS showed higher thrombogenicity in 25.9% of patients. There were no significant differences in the specificity of the TGA test between the groups of patients exhibiting similar clinical manifestations. Receiver operating characteristic curve analysis showed a more significant relationship (p = 0.0060) for TGA than for LA titre (p = 0.3387). These data suggest that the determination of LA thrombogenicity with the TGA assay leads to an increased prediction of the manifestation of a thromboembolic event. Our findings appear to be particularly relevant for the prediction of thrombotic events in patients with laboratory-expressed APS and no clinical manifestations.

• Publikační typ
• časopisecké články MeSH